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Huntington’s disease, the most common inherited neurodegener-
ative disease, is characterized by a dramatic loss of deep-layer
cortical and striatal neurons, as well as morbidity in midlife. Hu-
man genetic studies led to the identification of the causative gene,
huntingtin. Recent genomic advances have also led to the identi-
fication of hundreds of potential interacting partners for hunting-
tin protein and many hypotheses as to the molecular mechanisms
whereby mutant huntingtin leads to cellular dysfunction and
death. However, the multitude of possible interacting partners
and cellular pathways affected by mutant huntingtin has compli-
cated efforts to understand the etiology of this disease, and to
date no curative therapeutic exists. To address the general prob-
lem of identifying the disease-phenotype contributing genes from
a large number of correlative studies, here we develop a synthetic
lethal screening methodology for the mammalian central nervous
system, called SLIC, for synthetic lethal in the central nervous sys-
tem. Applying SLIC to the study of Huntington’s disease, we identify
the age-regulated glutathione peroxidase 6 (Gpx6) gene as a modu-
lator of mutant huntingtin toxicity and show that overexpression of
Gpx6 can dramatically alleviate both behavioral and molecular phe-
notypes associated with a mouse model of Huntington’s disease.
SLIC can, in principle, be used in the study of any neurodegenerative
disease for which a mouse model exists, promising to reveal mod-
ulators of neurodegenerative disease in an unbiased fashion, akin
to screens in simpler model organisms.
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All of the major neurodegenerative diseases display charac-teristic nerve-cell (neuronal) vulnerability patterns, as well as
an increased prevalence with advanced age. Due to the latter, it
has been reasoned that knowledge of the normal aging-associated
gene expression changes in vulnerable neuronal populations
would reveal pathways that intersect with disease-associated mo-
lecular mechanisms. Numerous studies have examined age-related
gene expression changes in human and rodent brain, revealing
altered expression of genes involved in many cellular processes,
including synaptic plasticity, mitochondrial function, proteasomal
function, antioxidant responses, as well as DNA damage repair (1–
4). However, these studies have focused almost exclusively on
gene expression changes averaged over entire brain regions
without resolving the multiple distinct neuronal cell types within
these regions. To study normal age-associated molecular pathways
in individual neurodegenerative disease-relevant cell types in situ,
we used the translating ribosome affinity purification (TRAP)
methodology (5, 6) to create cell-type–specific molecular profiles
of cell populations during normal mouse brain aging. Due to their
vulnerability in Huntington’s disease (HD), we profiled dop-
aminoceptive neurons in the striatum and cortex, as defined by
cells that express the Drd1a or Drd2 dopamine receptors at 6 wk
and 2 y of age (all research involving vertebrate animals was ap-
proved by the MIT institutional review board). Each cell type
displayed a unique pattern of gene expression changes associated
with aging that were consistent across technical replicates and
across mice (Datasets S1–S4 and Fig. 1). Only five genes, including
two predicted pseudogenes, displayed a statistically significant
altered expression with aging in all cell types (Tnnt2, Gm5425,
Rnd3, Pisd, and Pisd-ps3), indicating that there is not a common
aging program across the cell types studied, but rather that even
closely related cell types show distinct molecular changes during
normal aging. Pathways analysis of age-regulated genes revealed
several molecular pathways altered by aging in each cell type
(Datasets S5–S8). In Drd2-expressing striatal neurons, which dis-
played the greatest number of altered gene pathways during aging,
“glutathione-mediated detoxification” and “glutathione redox
reactions” were among the top gene pathways altered with age
(including the genesGsta3,Gsta4,Gstm1,Gstm6,Gpx1,Gpx2, and
Gpx6). Oxidative damage has long been linked to aging (7). Given
that oxidative damage to DNA, proteins, and lipids has been
reported to increase with age in the brain (8–10), the increases to
glutathione-dependent enzymes that we report here likely reflect
a homeostatic neuronal response to increased oxidative damage in
this cell population.
Although these experiments identified a promising set of age-
regulated candidate genes that may be relevant to the age-associ-
ated progression of Huntington’s disease, they did not single out any
one factor as contributing above others. In addition, the large ag-
gregate number of changes observed in these cell types prevented
us from inspecting the effects of each gene expression change on
Huntington’s disease progression with traditional means such as
mouse knockout or overexpression studies. To address this
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We describe here the application of genetic synthetic lethal
screening to the mammalian central nervous system. The
principle of synthetic lethality is that factors that are dispens-
able in a healthy cell are rendered essential in a diseased cell;
these factors thus define the pathways responsible for in-
creased cellular vulnerability in that disease. Our synthetic le-
thality screening in mouse models of Huntington’s disease (HD)
reveals that a glutathione peroxidase, Gpx6, can regulate the
emergence of HD model symptoms in mice.
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problem, we sought to develop a genetic screening platform that
could be used in the mammalian nervous system in a fashion similar
to the way that genetic screens are used in simpler model organisms
such as Caenorhabditis elegans and Drosophila melanogaster. We
term this methodology SLIC (for synthetic lethal in the CNS). SLIC
is composed of four parts: a short hairpin RNA (shRNA) library,
stereotaxic intracranial injection, mouse models of disease, and
DNA sequencing (Fig. 2). The principle of synthetic lethality is that
factors that are dispensable in a healthy cell are rendered essential
in a diseased cell; these factors thus define the pathways responsible
for increased cellular vulnerability in that disease. To identify syn-
thetic lethal interactions, SLIC uses a pooled screen approach that
was pioneered in yeast (11) and that has been adapted to identify
tumor suppressors and oncogenes in mammalian cancer models
(12–15). In SLIC, each neuron in a defined brain region receives
a single perturbation, in this case a lentivirus encoding an shRNA,
allowing many perturbations to be tested simultaneously in a sin-
gle mouse, as opposed to one mouse being used as a screening
vehicle for a single perturbation as in traditional knockout or
knockdown experiments. Based on test injections into the mouse
striatum, we calculate that we can transduce up to 2.8 × 105
striatal cells per mouse (SI Appendix, Fig. S1) and that over 80%
of viral-transduced cells are neurons (SI Appendix, Fig. S2).
For our first SLIC screen, we focused on Huntington’s disease,
as it is an ideal test case for a genetic screen: the disease is
monogenic, affects defined cell populations in an age-dependent
manner, and several mouse models have been created that dis-
play minimal cell loss. This latter feature is particularly advan-
tageous to our screening scheme, as synthetic lethal screens
require a mild phenotype around which to screen for an en-
hanced phenotype. We performed a SLIC screen in the R6/2
Huntington’s disease model line (16), seeking genes that, when
knocked down, would enhance mutant huntingtin toxicity. We
used 95 shRNAs in our screen (Dataset S9), including 1 positive
control shRNA, 7 negative control shRNAs, and 87 shRNAs
targeting 28 candidate genes. The 28 candidates included 19
genes identified in our cell-type–specific aging study, six genes
previously linked to Huntington’s disease, and three randomly
chosen genes (see Dataset S9 for details). Viral pools were
injected bilaterally into mouse striata of disease model and
control littermates at 6 wk of age. Genomic DNA was then
harvested at a control time point (2 d postinjection, once the
lentivirus has integrated into the cellular DNA but before sig-
nificant target protein knockdown), and two experimental time
points at which we expected to observe synthetic lethality (4 and
6 wk postinjection). Finally, shRNA-coding sequences were am-
plified and sequenced to assess the relative abundance of the 95
shRNAs in the pool.
To validate our SLIC approach, we first focused on the positive
and negative control shRNAs included in our screen. Comparison
of viral shRNA representation in the wild-type control (non-
model) mouse striatal samples at 4 wk versus 2 d revealed that
the positive control lentivirus, carrying an shRNA targeting the
Psmd2 gene product (a proteasomal subunit, depletion of which
is expected to lead to cell death), was greatly reduced in repre-
sentation, whereas negative controls, which have no expected
target in the mouse genome, were not reduced in representation
(Fig. 3A). We next asked which shRNAs were lost to a higher
degree from R6/2 Huntington’s disease model mice versus con-
trol littermates at the 4 and 6 wk experimental time points. This
comparison revealed that all shRNAs targeting Gpx6, a glutathi-
one peroxidase that by homology is predicted to detoxify H2O2 to
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Fig. 1. Gene expression changes associated with normal aging in cortical and striatal dopaminoceptive cell types. Venn diagram showing the number and
overlap of statistically significant gene expression changes in dopamine receptor 1a (D1)- or dopamine receptor 2 (D2)-expressing cortical or striatal neurons,
based on a comparison of mice aged 6 wk of age versus 2 y of age. Statistically significant changes are defined as genes displaying ≥1.2-fold change and
a Benjamini–Hochberg adjusted P value from Welch’s t test of ≤0.05.
Lentiviral library
Incubate in vivo
Fig. 2. Synthetic lethal in the CNS (SLIC) screening. (Top) Lentiviral knock-
down libraries are injected into the striatum, such that each neuron or glial
cell receives a distinct element (schematized by different colors). Lentivirus
integrates into the cell’s genome and expresses either a cDNA or shRNA.
(Bottom) After incubation in vivo, cells that have received a synthetic lethal
hit will die (*) and the representation of these library elements will be lost
(an event that can be revealed by sequencing of all of the lentiviruses still
present in the brain). As neurons in adult animals do not proliferate, the
change in abundance detected by sequencing is due to cell loss. When
injections are performed in a paired fashion, comparing disease model mice
to wild-type littermates, genes that cause synthetic lethality only in combi-
nation with a disease-causing mutation can be identified.
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water, demonstrated synthetic lethality with mutant huntingtin.
Using a gene-scoring scheme that incorporates the synthetic le-
thality ranks of the top two shRNAs for each gene, Gpx6 was the
top-ranking gene at both the 4 and 6 wk time points (Fig. 3 B and C;
Datasets S10–S12; SI Appendix). We also observed several shRNAs
that were depleted in wild-type cells, and thus presumably are
deleterious even in healthy cells. Importantly, these shRNAs were
lost to an equal or lesser extent in R6/2 brains, demonstrating that
the Gpx6 interaction is specific and not a consequence of cells in the
disease model showing increased vulnerability to a broad spectrum
of potential cell stressors (Fig. 3B).
Because little is known about Gpx6 function and expression,
we next assessed its distribution across brain region and age. We
found Gpx6 to be highly expressed in the olfactory bulb, stria-
tum, and frontal cerebral cortex (SI Appendix, Fig. S3) and,
confirming our TRAP results, observed that Gpx6 expression
increases with age (SI Appendix, Fig. S4). Because our screen
identified Gpx6 as a gene that, when reduced, enhances mutant
huntingtin toxicity, we next asked whether overexpression of this
gene product would have a therapeutic effect on phenotype
progression in a Huntington’s disease mouse model. We over-
expressed Gpx6 in the striatum of the R6/2 model and congenic
wild-type control mice via adeno-associated viral (AAV) trans-
duction starting at 6 wk of age. Two weeks after viral injection,
we observed a dramatic rescue of open-field and rota-rod motor
behavior in R6/2 mice, but no effect on motor behavior in wild-
type control mice (Fig. 4A and SI Appendix, Fig. S6). Finally,
analysis of a molecular marker of Huntington’s disease pro-
gression, loss of DARPP-32 striatal expression (17), revealed
that Gpx6 overexpression also increases DARPP-32 expression
in the R6/2 model (Fig. 4B). Thus, Gpx6 overexpression protects
against both behavioral and molecular phenotypes associated
with disease progression in this mouse model.
Our data demonstrate that our SLIC methodology can be used
to identify genes that display synthetic lethality in combina-
tion with a disease-associated mutation. This screen tested 95
shRNAs using just a single mouse brain hemisphere per replicate,
demonstrating its power and scaleability. In principle, both ge-
nome-wide overexpression and knockdown screens can be con-
ducted in the mammalian central nervous system using SLIC. Our
screen used constitutively expressing lentiviruses to target all
striatal cells, but increased cellular specificity could be achieved
through use of conditional systems such as the TVA/EnvA system
(18). The gene identified in our screen as enhancing the toxicity of
mutant huntingtin when knocked down, Gpx6, is particularly ap-
pealing given the abundant literature linking oxidative stress to
Huntington’s disease pathophysiology (19), a study reporting that
mice deficient in cellular glutathione peroxidase show enhanced
vulnerability to a chemical model of Huntington’s disease (20),
a recent study identifying glutathione peroxidase activity as a sup-
pressor of mutant Huntingtin toxicity in yeast (21), and a study
reporting Gpx6 protein levels to be altered in the striatum of hu-
man Huntington’s disease patients (22). Furthermore, blood–brain
barrier-penetrant, orally active glutathione peroxidase-mimicking
Fig. 3. SLIC screening in mouse models of Huntington’s disease. (A) Changes in control shRNA representation, as determined by sequencing, in the striatum
of wild-type animals at 4 and 6 wk after injection compared with the control 2-d time point. A negative number reflects loss versus the control time point.
Error bars reflect ±SD across shRNAs. (B) shRNA representation at the first SLIC HD time point. The log2 fold changes in shRNA representation at 4 wk
compared with the control 2-d time point for the HD model (R6/2, y axis) are plotted versus the log2 fold changes at the same two time points for wild-type
controls (WT, x axis). The positive control targeting the Psmd2 gene product is not plotted for the purposes of scaling. Diagonal line represents equal
representation for visual reference (x = y). Genes causing synthetic lethality are expected to be offset to the right of the diagonal. Gpx6-targeting shRNAs are
denoted in red. (C) SLIC results for shRNAs showing synthetic lethality in the HD model. The y axes show the percentage of depletion of the indicated shRNAs
in the HD model compared with wild-type controls, where “depletion” is defined as “the log2 fold change in representation between early (2 d) and late
(4 wk, Left; 6 wk, Right) time points in each genotype” and “% depletion” is defined as “the difference in depletion in the disease model relative to wild-type
controls {[(WT-R6/2)/WT] × 100}.” Sample values were averaged across four replicates. Multiple annotations of the same target gene on the x axis represent
distinct shRNAs targeting these genes. Gpx6-targeting shRNAs are denoted in red.
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hydrogen peroxide scavengers have been identified (23, 24). Given
that Gpx6 interacts genetically with the mutant huntingtin, and that
we find that it is up-regulated with age, our screen suggests that
increases to reactive oxygen species (hydrogen peroxide in partic-
ular) contribute to the enhancement of mutant huntingtin toxicity
that is seen with advancing age.
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